Ambulatory Care Self-Assessment Program (ACSAP) Book 3: Gastrointestinal and Nutrition Care (Cert # L239371)

The target audience for Ambulatory Care Self-Assessment Program (ACSAP) Book 3: Gastrointestinal and Nutrition Care is board-certified and advanced level ambulatory care clinical pharmacists.

Board certified pharmacists are eligible to receive up to 19.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Gastrointestinal and Nutrition Care I
ACPE #: 0217-9999-23-212-H01-P
Chapter: Hepatitis B and C

• Analyze hepatitis B virus (HBV) serology to identify patients who would benefit from vaccination and those who require additional evaluation and monitoring.
• Distinguish patients who are candidates for treatment of chronic HBV, and make appropriate treatment recommendations.
• Discover distinctions between hepatitis C virus (HCV) antiviral regimens, including dosing, drug interactions, and applications for special populations.
• Design evidence-based HCV regimens on the basis of individual patient characteristics. 

Chapter: Inflammatory Bowel Disease

• Distinguish between Crohn disease (CD) and ulcerative colitis (UC), including disease severity classifications.
• Assess goals of therapy and efficacy for people receiving treatment for inflammatory bowel disease (IBD).
• Evaluate the efficacy and safety data for medications used to treat IBD.
• Develop evidence-based, person-centered treatment regimens for IBD that incorporate laboratory monitoring, immunization considerations, pharmacologic and nonpharmacologic treatment recommendations, counseling points, and consideration of drug-specific factors. 

Gastrointestinal and Nutrition Care II
ACPE #: 0217-9999-23-213-H01-P
Chapter: Irritable Bowel Syndrome

• Distinguish between different types of irritable bowel syndrome (IBS).
• Assess the efficacy and safety data for medications used to treat IBS with diarrhea (IBS-D) and IBS with constipation (IBS-C).
• Devise a treatment plan for patients, considering drug-specific factors for medications used to treat IBS.
• Develop evidence-based, patient-centered treatment regimens for IBS considering drug-specific factors. 

Chapter: Celiac Disease

• Analyze the epidemiology and pathophysiology of celiac disease (CD) and the impact on a patient’s health and wellness.
• Evaluate the clinical presentation (i.e., symptoms, laboratory findings, medical history, risk factors, and complications) of a patient with CD.
• Assess the effectiveness and safety of current therapeutic strategies for CD, including both dietary and pharmacotherapeutic options.
• Distinguish regulatory standards and guidelines for gluten products and how to safely select food, supplements, and pharmaceutical products.
• Develop a plan to prevent and manage nutritional deficiencies in a patient with CD. 

Gastrointestinal and Nutrition Care III
ACPE #: 0217-9999-23-214-H01-P
Chapter: Medication Use After Bariatric Surgery

• Discover appropriate and inappropriate medications used after bariatric surgery.
• Design a plan for treating or preventing vitamin deficiencies in patients after bariatric surgery.
• Design a plan for treating or preventing complications in patients during perioperative bariatric surgery.
• Resolve drug therapy problems associated with medications after bariatric surgery.
• Assess disease states that benefit from bariatric surgery. 

Gastrointestinal and Nutrition Care IV
ACPE #: 0217-9999-23-215-H01-P
Chapter: Clostridioides difficile Infection

• Assess patients for risk factors for Clostridioides difficile infection (CDI).
• Design a patient-specific treatment plan for themanagement of CDI.
• Develop educational material and counseling tips for patients receiving treatment for CDI.
• Devise strategies to prevent the development and transmission of CDI. 

Chapter: Weight Management

• Distinguish among nonpharmacologic approaches to weight management.
• Assess the efficacy and safety data for medications used in weight management.
• Design a treatment plan for a patient desiring to lose weight, including patients of special populations.
• Assess the pharmacist’s role in weight management. 

Gastrointestinal and Nutrition Care V
ACPE #: 0217-9999-23-216-H01-P
Interactive Case: Proton Pump Inhibitor Deprescribing

• Analyze risks associated with long-term proton pump inhibitor (PPI) use.
• Distinguish patients who are candidates for PPI deprescribing from those who are not.
• Assess evidence-based resources available for PPI deprescribing.
• Develop a clinical care plan for deprescribing PPIs when given a patient case. 

Interactive Case: Nonprescription Gastrointestinal Disorder Treatment

• Demonstrate a systematic approach to evaluate a patient seeking nonprescription medication for common GI concerns.
• Evaluate the appropriateness of treating a patient’s symptoms with nonprescription medication, and distinguish patients who are not candidates for self-care and should be referred.
• Develop a pharmacologic and nonpharmacologic plan for a patient with common GI concerns. 

Recorded Webcast: Nausea and Vomiting

• Distinguish the differences between the different etiologies, risk factors, and causes of nausea and vomiting (N/V) syndromes, including general, chemotherapy induced, radiation induced, postoperative, and pregnancy induced.
• Evaluate the available nonpharmacologic and pharmacologic therapies with respect to mechanism of action, clinical uses, and drug-specific factors.
• Analyze the available literature and guidelines surrounding the treatment of various types of N/V.
• Develop evidence-based treatment regimens for N/V considering the etiology, risk factors, and drug-specific factors.

Faculty Information

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

Consultancies: Shubha Bhat (Bristol Myers Squibb; AbbVie; Boehringer Ingelheim; Pfizer; Prometheus Laboratories; Pharmacosmos);
Elias B. Chahine (Seqirus; Gilead; Shionogi; Theratechnologies); David K. Choi (Bristol Myers Squibb; Prometheus Laboratory;
Boehringer Ingelheim; AbbVie); Joseph Fava (Moderna); Wesley D. Kufel (Theratechnologies)

Stock Ownership: Melissa A. Pendoley (Eli Lilly)

Grants: Wesley D. Kufel (Melinta; Merck)

Honoraria: Shubha Bhat (Prometheus Laboratories; Fresenius Kabi); David K. Choi (Janssen Pharmaceuticals)

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

• Complete the attestation statement
• Review all content
• Complete and pass the assessments
• Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ACCP and ASHP collaborate on ambulatory care pharmacy activities.